Call for Innovative Project Applications
The Cooperative Study Group for Autoimmune Disease Prevention invites applications for new pilot project awards. Proposals for pilot awards must be consistent with the overall goal of the program, "to engage in scientific discovery which significantly advances knowledge of progression and regulation of autoimmune disease." Pilot projects initiated by the Study Group serve as a mechanism for the rapid testing of new ideas and technologies potentially applicable to the overall objectives of the program. Awards are typically one year in duration with a direct cost budget of $50,000 to $75,000. Successful applicants will be expected to participate in an annual scientific meeting of Study Group investigators.
Particularly encouraged are proposals:
- to create improved models of disease pathogenesis and therapy, and to use these models as validation platforms with which to test new tools applicable to human studies
- to encourage core expertise and collaborative projects designed for rapid translation from murine to human studies, emphasizing the development of surrogate markers for disease progression and/or regulation which can be utilized in the context of clinical trials
- from young investigators, especially those new to the field of autoimmunity
- for multi-institutional collaborative studies
Applications for this review cycle must be received by e-mail to tesch@niaid.nih.gov no later than April 29, 2008.
Applications must be five pages or less, plus a one-page NIH-style cover page and one-page NIH-style budget and justification (maximum request $75,000 for one year). New investigators should include an NIH-style CV. Applications will be reviewed in May 2008, with a potential award start date of 1 June 2008.
Investigators who are unfamiliar with the Study Group and its procedures or who have questions about the suitability of a potential application are encouraged to contact a member of the Steering Committee for advice (see Cooperative Study Group for Autoimmune Disease Prevention).
back to top